Federated Hermes Inc. Purchases Shares of 124,620 Keros Therapeutics, Inc. (NASDAQ:KROS)

Federated Hermes Inc. purchased a new stake in Keros Therapeutics, Inc. (NASDAQ:KROS - Free Report) during the fourth quarter, according to the company in its most recent filing with the SEC. The firm purchased 124,620 shares of the company's stock, valued at approximately $1,973,000. Federated Hermes Inc. owned about 0.31% of Keros Therapeutics as of its most recent SEC filing.

Other institutional investors also recently made changes to their positions in the company. Geode Capital Management LLC lifted its holdings in Keros Therapeutics by 6.8% in the 3rd quarter. Geode Capital Management LLC now owns 725,621 shares of the company's stock worth $42,146,000 after buying an additional 46,041 shares in the last quarter. SG Americas Securities LLC acquired a new stake in Keros Therapeutics during the 4th quarter valued at approximately $388,000. Barclays PLC increased its holdings in Keros Therapeutics by 140.1% during the 3rd quarter. Barclays PLC now owns 60,014 shares of the company's stock worth $3,484,000 after purchasing an additional 35,022 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. acquired a new position in shares of Keros Therapeutics in the 4th quarter valued at approximately $461,000. Finally, American Century Companies Inc. boosted its stake in shares of Keros Therapeutics by 10.5% during the 4th quarter. American Century Companies Inc. now owns 328,920 shares of the company's stock valued at $5,207,000 after buying an additional 31,251 shares during the last quarter. 71.56% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In other Keros Therapeutics news, major shareholder Adar1 Capital Management, Llc bought 934,258 shares of Keros Therapeutics stock in a transaction on Wednesday, April 9th. The stock was purchased at an average cost of $10.13 per share, for a total transaction of $9,464,033.54. Following the completion of the purchase, the insider now directly owns 4,392,737 shares of the company's stock, valued at $44,498,425.81. The trade was a 27.01 % increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 22.90% of the stock is currently owned by corporate insiders.

Remove Ads

Wall Street Analysts Forecast Growth

KROS has been the subject of a number of research reports. Piper Sandler decreased their target price on Keros Therapeutics from $40.00 to $15.00 and set an "overweight" rating for the company in a research note on Friday, January 17th. Wells Fargo & Company cut their target price on Keros Therapeutics from $28.00 to $26.00 and set an "overweight" rating on the stock in a research note on Thursday, February 27th. Guggenheim restated a "neutral" rating on shares of Keros Therapeutics in a research report on Friday, January 17th. Cantor Fitzgerald downgraded shares of Keros Therapeutics from an "overweight" rating to a "neutral" rating in a research report on Tuesday, January 21st. Finally, Truist Financial decreased their target price on shares of Keros Therapeutics from $43.00 to $25.00 and set a "buy" rating for the company in a research report on Wednesday, April 9th. Six equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and an average price target of $40.33.

Keros Therapeutics Price Performance

Shares of KROS traded up $0.35 during mid-day trading on Tuesday, hitting $13.09. The company's stock had a trading volume of 1,084,541 shares, compared to its average volume of 773,949. The stock has a market capitalization of $530.96 million, a price-to-earnings ratio of -2.51 and a beta of 1.39. Keros Therapeutics, Inc. has a fifty-two week low of $9.12 and a fifty-two week high of $72.37. The firm has a 50-day moving average price of $10.97 and a 200 day moving average price of $30.19.

Keros Therapeutics (NASDAQ:KROS - Get Free Report) last issued its quarterly earnings results on Wednesday, February 26th. The company reported ($1.14) EPS for the quarter, beating the consensus estimate of ($1.36) by $0.22. Keros Therapeutics had a negative net margin of 27,890.94% and a negative return on equity of 41.74%. The business had revenue of $3.04 million during the quarter, compared to the consensus estimate of $37.32 million. As a group, equities analysts anticipate that Keros Therapeutics, Inc. will post -4.74 EPS for the current fiscal year.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.